Ischemia Technologies Inc.

Normally a low-profile player in point-of-care diagnostics, Inverness amped up its acquisition strategy by spending nearly $2 billion to acquire Biosite and Cholestech. It’s showing no buyer’s remorse

By borrowing ideas from a variety of early-stage funding schemes, Scotland's ITI Life Sciences has created a unique model for plugging the widening funding gap between publicly funded research and ven

Ischemia Technologies' launch strategy for its new cardiac marker is based on tenets gleaned from recent diagnostic success stories. But the inherent complexities of the opportunity it addresses are c

The cardiac marker field, dormant for years, is changing so rapidly that studies done five years ago are completely out of date. Interest in the field is keen for good reason: current markers are incr